

DAFTAR PUSTAKA

1. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. Vol. 80, *Journal of the American College of Cardiology*. American College of Cardiology Foundation Washington DC; 2022. p. 2361–71.
2. Hussain MA, Al Mamun A, Peters SAE, Woodward M, Huxley RR. The burden of cardiovascular disease attributable to major modifiable risk factors in Indonesia. *J Epidemiol*. 2016;26(10):515–21.
3. Uli RE, Satyana RPU, Zomer E, Magliano D, Liew D, Ademi Z. Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling. *BMJ Open*. 2020;10(9):e039221.
4. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. In: *Mayo Clinic Proceedings*. Elsevier; 2009. p. 917–38.
5. Adhitya AS, Hasan H, Hasan R, Siregar AA, Mukhtar Z, Nasution AN. Comparison of TIMI Flow in STEMI Patients With and Without Resolution on Reciprocal ST Segment Depression Obtaining Fibrinolytic Alteplase Therapy. *ACI (Acta Cardiologia Indonesiana)*. 5(2):129–35.
6. Group I 2 C. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. *ISIS-2. Lancet*. 1988;49–360.
7. Vicent L, Diaz-Arocutipa C, Tarantini G, Mojoli M, Hernandez A V, Bueno H. Early vs. Delayed Initiation of Treatment With P2Y12 Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. *Front Cardiovasc Med*. 2022;9.
8. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *New England Journal of Medicine*. 2005;352(12):1179–89.
9. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *New England Journal of Medicine*. 2009;361(11):1045–57.
10. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *New England Journal of Medicine*. 2007;357(20):2001–15.
11. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. *New England Journal of Medicine*. 2015 May 7;372(19):1791–800.
12. Jeong YH, Tantry US, Omar M, Navarese E, Gorog DA, Gurbel PA. “East Asian Paradox” Revisited: Precision Medicine for Antithrombotic Strategies Tailored to Atherothrombotic Cardiovascular Risks. *Journal of Cardiovascular Intervention*. 2024;3(3):119.
13. Kang J, Kim HS. The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox.” *Korean Circ J*. 2018;48(7):537.
14. Misumida N, Aoi S, Kim SM, Ziada KM, Abdel-Latif A. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: systematic review and meta-analysis. *Cardiovascular Revascularization Medicine*. 2018;19(6):689–94.

15. Wu B, Lin H, Tobe RG, Zhang L, He B. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. *J Comp Eff Res*. 2018;7(3):281–91.
16. Galimzhanov AM, Azizov BS. Ticagrelor for Asian patients with acute coronary syndrome in real-world practice: A systematic review and meta-analysis of observational studies. *Indian Heart J*. 2019;71(1):15–24.
17. Sun M, Cui W, Li L. Comparison of clinical outcomes between ticagrelor and clopidogrel in acute coronary syndrome: a comprehensive meta-analysis. *Front Cardiovasc Med*. 2022;8:818215.
18. Yun JE, Kim YJ, Park JJ, Kim S, Park K, Cho MS, et al. Safety and effectiveness of contemporary P2Y12 inhibitors in an East Asian population with acute coronary syndrome: a nationwide population-based cohort study. *J Am Heart Assoc*. 2019;8(14):e012078.
19. Martha JW, Sihite TA, Listina D. The Difference in Accuracy Between Global Registry of Acute Coronary Events Score and Thrombolysis in Myocardial Infarction Score in Predicting In-Hospital Mortality of Acute ST-Elevation Myocardial Infarction Patients. *Cardiol Res*. 2021 Jun;12(3):177–85.
20. Dai W, Ye Z, Li L, Su Q. Effect of preoperative loading dose ticagrelor and clopidogrel on no-reflow phenomenon during intervention in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. *Drug Des Devel Ther*. 2018 Jul;Volume 12:2039–49.
21. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, et al. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention. *Circulation*. 2010 Nov 23;122(21):2131–41.
22. Junior Rina Artha IM, Juzar DA, Prana Jagannatha GN, de Liyis BG, Kosasih AM, Juliantara AAPE, et al. Clinico-demographical differences and seven years management performance of acute coronary syndrome in Bali, Indonesia. *Clin Epidemiol Glob Health*. 2024 Nov;30:101847.
23. Naithani N, Sinha S, Misra P, Vasudevan B, Sahu R. Precision medicine: Concept and tools. *Med J Armed Forces India [Internet]*. 2021 Jul 1 [cited 2025 Oct 4];77(3):249. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC8282508/>
24. Jeong YH, Obayashi Y, Song H, Kimura T. Still a Long Way to the Precision Medicine of Antiplatelet Strategy After Percutaneous Coronary Intervention. *Circ Cardiovasc Interv [Internet]*. 2022 Aug 1 [cited 2025 Oct 4];15(8):E012261. Available from: <https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.122.012261>
25. Stark B, Johnson C, Roth GA. GLOBAL PREVALENCE OF CORONARY ARTERY DISEASE: AN UPDATE FROM THE GLOBAL BURDEN OF DISEASE STUDY. *J Am Coll Cardiol*. 2024 Apr;83(13):2320.
26. Shahab A, Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S. *Komplikasi Kronik Diabetes Mellitus Dan Penyakit Jantung Koroner*. 2013th ed. Leong BDK, editor. Jakarta: Departemen Ilmu Penyakit Dalam FKUI; 2007. 10–12 p.
27. Leong BD, Ariffin AZ, Chuah JA, Voo SY. Prevalence of peripheral arterial disease and abdominal aortic aneurysm among patients with acute coronary syndrome. *Med J Malaysia*. 2013;68(1):10–2.
28. Laporan Riskesdas 2018 Nasional.
29. Statistik Jaminan Kesehatan Nasional Tahun 2016-2021. Jakarta: Dewan Jaminan Kesehatan Nasional; 2022.
30. Joseph P, Yusuf S, Lee SF, Ibrahim Q, Teo K, Rangarajan S, et al. Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. *Heart*. 2018;104(7):581–7.

31. McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A, et al. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. *Eur Heart J*. 2011;32(5):581–9.
32. Ambrose JA, Singh M. Pathophysiology of coronary artery disease leading to acute coronary syndromes. *F1000Prime Rep*. 2015;7.
33. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140(11):e563–95.
34. Aziz S, Ramsdale DR. Chronic total occlusions—a stiff challenge requiring a major breakthrough: is there light at the end of the tunnel? *Heart*. 2005;91(suppl 3):iii42–8.
35. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus—mechanisms, management, and clinical considerations. *Circulation*. 2016;133(24):2459–502.
36. Zipes DP. Braunwald’s heart disease: a textbook of cardiovascular medicine. *BMJ Medical Journal-ISSN 2348–392X*. 2018;5(2):63.
37. Palasubramaniam J, Wang X, Peter K. Myocardial infarction—From atherosclerosis to thrombosis: Uncovering new diagnostic and therapeutic approaches. *Arterioscler Thromb Vasc Biol*. 2019;39(8):e176–85.
38. Libby P, Theroux P. Pathophysiology of coronary artery disease. *Circulation*. 2005;111(25):3481–8.
39. Mackman N, Spronk HMM, Stouffer GA, Ten Cate H. Dual anticoagulant and antiplatelet therapy for coronary artery disease and peripheral artery disease patients. *Arterioscler Thromb Vasc Biol*. 2018;38(4):726–32.
40. Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. *Circ Res*. 2016;118(9):1392–408.
41. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. *Journal of nuclear medicine*. 2007;48(11):1800–15.
42. Stojanović SD, Fiedler J, Bauersachs J, Thum T, Sedding DG. Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. *Eur Heart J*. 2020;41(31):2983–96.
43. Dinarello CA. Proinflammatory cytokines. *Chest*. 2000;118(2):503–8.
44. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. *Circ Res*. 2016;118(1):145–56.
45. Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, et al. A guiding map for inflammation. *Nat Immunol*. 2017;18(8):826–31.
46. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *New England journal of medicine*. 2017;377(12):1119–31.
47. Wainstein M V, Mossmann M, Araujo GN, Gonçalves SC, Gravina GL, Sangalli M, et al. Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography. *Diabetol Metab Syndr*. 2017;9(1):1–7.
48. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. *JAMA*. 2003;290(7):932–40.

49. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation*. 2003;107(3):363–9.
50. Chandrashekhara S. C-reactive protein: An inflammatory marker with specific role in physiology, pathology, and diagnosis. *Internet Journal of Rheumatology and Clinical Immunology*. 2014;2(S1).
51. Salazar J, Martínez MS, Chávez-Castillo M, Núñez V, Añez R, Torres Y, et al. C-reactive protein: an in-depth look into structure, function, and regulation. *Int Sch Res Notices*. 2014;2014.
52. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. *Front Immunol*. 2018;9:754.
53. Dhingra R, Gona P, Nam BH, D'Agostino Sr RB, Wilson PWF, Benjamin EJ, et al. C-reactive protein, inflammatory conditions, and cardiovascular disease risk. *Am J Med*. 2007;120(12):1054–62.
54. Bansal S, Ridker PM. Comparison of characteristics of future myocardial infarctions in women with baseline high versus baseline low levels of high-sensitivity C-reactive protein. *Am J Cardiol*. 2007;99(11):1500–3.
55. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Atherosclerosis*. 2019;290:140–205.
56. McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. *Nat Rev Cardiol*. 2018;15(3):181–91.
57. Weitz JI. Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs. *Goodman & Gilman's: The Pharmacological Basis of Therapeutics 12th ed* New York, New York: McGraw-Hill Medical. 2011;869–70.
58. Karha J, Cannon CP. ADP receptor antagonists. In: *Platelets in Cardiovascular Disease*. World Scientific; 2008. p. 87–123.
59. Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. *Eur Heart J*. 2009;30(16):1964–77.
60. Andersen K, Cogan P. Anticoagulants and Antiplatelet Agents. In: *Lippincott Illustrated Reviews: Pharmacology*. 6th ed. Philadelphia: Wolters Kluwer; 2015. p. 291–8.
61. Avanzas P, Morís C, Clemmensen P. Antiplatelet therapy. New potent P2Y12 inhibitors. In: *Pharmacological Treatment of Acute Coronary Syndromes*. Springer; 2013. p. 31–57.
62. Fox KAA, White HD, Gersh BJ, Opie LH. Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics and chronic anticoagulants. *Drugs for the heart*. 2013;
63. Dulin BR, Steinhubl SR. Thromboxane antagonists. *Platelets in cardiovascular disease*. 2008;37–63.
64. Li YR. Anticoagulants, Platelet Inhibitors, and Thrombolytic Agents. In: *Cardiovascular Diseases: From Molecular Pharmacology to Evidence-Based Therapeutics*. USA: Wiley; 2015. p. 295–304.
65. Jing F, Zhang W. Thrombosis therapy: focus on antiplatelet Agents. *International Journal of Genomic Medicine*. 2013;1–8.
66. Jaffer I, Weitz J. Antithrombotic Drugs. In: *Hematology: Basic Principles and Practice*. 7th ed. Philadelphia: Elsevier; 2018. p. 2168–73.
67. Kalantzi KI, Tsoumani ME, Goudevenos IA, Tselepis AD. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. *Expert Rev Clin Pharmacol*. 2012;5(3):319–36.

68. Hasan MS, Basri H Bin, Hin LP, Stanslas J. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. *International Journal of Neuroscience*. 2013;123(3):143–54.
69. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. *The Lancet*. 2015;386(9990):281–91.
70. Teng R. Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update. *Clin Pharmacokinet*. 2015;54:1125–38.
71. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. *Anesth Analg*. 2011;112(2):292–318.
72. Khan MG, Khan MG. Antiplatelet Agents, Anticoagulants, Factor Xa Inhibitors, and Thrombin Inhibitors. *Cardiac Drug Therapy*. 2015;593–621.
73. Association IH. *Pedoman Tata Laksana Sindrom Koroner Akut (Edisi Keempat)*. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). 2018;
74. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2021;42(14):1289–367.
75. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. *J Am Coll Cardiol*. 2007;49(24):2312–7.
76. Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, et al. Predictive Values of Post-Treatment Adenosine Diphosphate-Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients. *Am J Cardiol*. 2009;104(8):1078–82.
77. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of periprocedural platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. *American Collage of Cardiology*. 2006;48:1742–50.
78. Geisler T, Zürn C, Simonenko R, Rapin M, Kraibooj H, Kilias A, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. *Eur Heart J*. 2010;31(1):59–66.
79. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. *J Am Coll Cardiol*. 2008;52(9):734–9.
80. Migliorini A, Valenti R, Marcucci R, Parodi G, Giuliani G, Buonamici P, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. *Circulation*. 2009;120(22):2214–21.
81. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. *J Am Coll Cardiol*. 2012;59(24):2159–64.

82. Collet JP, Cayla G, Cuisset T, Elhadad S, Rangé G, Vicaut E, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. *Am Heart J*. 2011;161(1):5–12.
83. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation*. 2015;131(4):e29–322.
84. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. *Eur Heart J*. 2011;32(23):2922–32.
85. James S, Åkerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, et al. Comparison of ticagrelor, the first reversible oral P2Y₁₂ receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATElet inhibition and patient Outcomes (PLATO) trial. *Am Heart J*. 2009;157(4):599–605.
86. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2018;39(3):213–60.
87. Kim HK, Tantry US, Smith Jr SC, Jeong MH, Park SJ, Kim MH, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. *Thromb Haemost*. 2021;121(04):422–32.
88. Oyatani K, Koyama M, Himuro N, Miura T, Ohnishi H. Characterization of prehospital time delay in primary percutaneous coronary intervention for acute myocardial infarction: Analysis of geographical infrastructure-dependent and-independent components. 2023;
89. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2018;39(2):119–77.
90. Henriques JPS, Zijlstra F, van 't Hof AWJ, de Boer MJ, Dambrink JHE, Gosselink M, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. *Circulation*. 2003;107(16):2115–9.
91. Group* TS. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. *New England Journal of Medicine*. 1985;312(14):932–6.
92. Tan WA, Moliterno DJ. TIMI flow and surrogate end points: what you see is not always what you get. Vol. 136, *American Heart Journal*. Mosby; 1998. p. 570–3.
93. van 't Hof AWJ, Liem A, Suryapranata H, Hoorntje JCA, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. *Circulation*. 1998;97(23):2302–6.
94. Poudel I, Tejpal C, Rashid H, Jahan N. Major adverse cardiovascular events: an inevitable outcome of ST-elevation myocardial infarction? A literature review. *Cureus*. 2019;11(7).
95. Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. *BMC Med Res Methodol*. 2021;21(1):1–18.

96. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). *Eur Heart J*. 2020;41(3):407–77.
97. Tsai I, Wang CP, Lu YC, Hung WC, Wu CC, Lu LF, et al. The burden of major adverse cardiac events in patients with coronary artery disease. *BMC Cardiovasc Disord*. 2017;17(1):1–13.
98. Yokoi H, Oda E, Kaneko K, Matsubayashi K. Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals. *Cardiovasc Interv Ther*. 2022 Jul 1;37(3):465–74.
99. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. *New England Journal of Medicine*. 2021 Oct 28;385(18):1643–55.
100. Rashid M, Abramov D, Naseer MU, Van Spall HGC, Ahmed FZ, Lawson C, et al. 15-Year trends, predictors, and outcomes of heart failure hospitalization complicating first acute myocardial infarction in the modern percutaneous coronary intervention era. *European Heart Journal Open*. 2025 Mar 1;5(2).
101. Alfredsson J, Omar K, Csog J, Venetsanos D, Janzon M, Ekstedt M. Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients—A real life cohort study of two treatment strategies. *IJC Heart & Vasculature*. 2020;27:100495.
102. Mehran R, Rao S V, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation*. 2011;123(23):2736–47.
103. McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. *Nat Rev Cardiol [Internet]*. 2018 Mar 1 [cited 2025 Sep 11];15(3):181–91. Available from: <https://pubmed.ncbi.nlm.nih.gov/29297508/>
104. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. *New England Journal of Medicine*. 2009 Sep 10;361(11):1045–57.
105. Evans W, Meslin EM, Kai J, Qureshi N. Precision Medicine—Are We There Yet? A Narrative Review of Precision Medicine’s Applicability in Primary Care. *J Pers Med*. 2024;14(4).
106. Muharremi G, Meçani R, Muka T. The Buzz Surrounding Precision Medicine: The Imperative of Incorporating It into Evidence-Based Medical Practice. *J Pers Med*. 2024;14(1).
107. Brew-Sam N, Parkinson A, Lueck C, Brown E, Brown K, Bruestle A, et al. The current understanding of precision medicine and personalised medicine in selected research disciplines: study protocol of a systematic concept analysis. *BMJ Open*. 2022;12(9):1–8.
108. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. *Clin Transl Sci*. 2021;14(1):86–93.
109. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. *Pharmaceutics*. 2024;16(3).
110. Gagnano F, Moscarella E, Calabro’ P, Cesaro A, Pafundi PC, Patti G, et al. Ticagrelor versus Clopidogrel in high bleeding risk patients presenting with Acute Coronary Syndromes: insights from the multicenter START-ANTIPLATELET registry. *Eur Heart J*. 2020;41(Supplement_2).

111. Ueki Y, Bär S, Losdat S, Otsuka T, Zanchin C, Zanchin T, et al. Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. *EuroIntervention*. 2020;16(5):371–9.
112. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: Lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. *Eur Heart J*. 2017;38(11):804–10.
113. Zocca P, Kok MM, van der Heijden LC, van Houwelingen KG, Hartmann M, de Man FHF, et al. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. *Int J Cardiol* [Internet]. 2018;268:11–7. Available from: <https://doi.org/10.1016/j.ijcard.2018.03.116>
114. De Luca L, Zeymer U, Claeys MJ, Dörler J, Erne P, Matter CM, et al. Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: A propensity score analysis of five contemporary European registries. *Eur Heart J Cardiovasc Pharmacother*. 2021;7(2):94–103.
115. Porta L, Baorda F, Fusco A. Is proton pump inhibitors' prophylaxis indicated for patients on antiplatelet therapy? *Intern Emerg Med* [Internet]. 2018;13(4):585–7. Available from: <https://doi.org/10.1007/s11739-018-1827-9>
116. Szummer K, Montez-Rath ME, Alfredsson J, Erlinge D, Lindahl B, Hofmann R, et al. Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome: Insights From the SWEDEHEART Registry. *Circulation*. 2020;142(18):1700–8.
117. Tjerkaski J, Jernberg T, Alfredsson J, Erlinge D, James S, Lindahl B, et al. Comparison between ticagrelor and clopidogrel in high bleeding risk patients with acute coronary syndrome. *Eur Heart J*. 2022;43(Supplement_2):2022.
118. Cavallari LH, Lee CR, Franchi F, Keeley EC, Rossi JS, Thomas CD, et al. Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies. *Clin Transl Sci*. 2024;17(8):1–11.
119. Gower MN, Ratner LR, Williams AK, Rossi JS, Stouffer GA, Lee CR. Clinical utility of cyp2c19 genotype-guided antiplatelet therapy in patients at risk of adverse cardiovascular and cerebrovascular events: A review of emerging evidence. *Pharmacogenomics Pers Med*. 2020;13:239–52.
120. DeVore AD, Bosworth HB, Granger BB. Improving implementation of evidence-based therapies for heart failure. *Clin Cardiol* [Internet]. 2022 Jun 1 [cited 2025 Oct 5];45(Suppl 1):S52. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9254671/>
121. Gao CZ, Ma QQ, Wu J, Liu R, Wang F, Bai J, et al. Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention: A Pilot Study. *Cellular Physiology and Biochemistry*. 2018;48(1):385–96.
122. Yang B, Zheng C, Yu H, Zhang R, Li S, Len M, et al. Comparison of efficacy between clopidogrel and ticagrelor in patients with acute coronary syndrome after interventional treatment and their effects on IL-6. *Iran J Public Health*. 2020;49(2):240–8.
123. Wei P, Wang X, Fu Q, Cao B. Progress in the clinical effects and adverse reactions of ticagrelor. *Thromb J* [Internet]. 2024 Dec 1 [cited 2025 Sep 6];22(1):1–9. Available from: <https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-023-00559-3>

124. Zhang Y, Zhao Y, Pang M, Wu Y, Zhuang K, Zhang H, et al. High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial. *Acta Cardiol*. 2016;71(3):309–16.
125. Angiolillo DJ, Franchi F, Waksman R, Sweeny JM, Raveendran G, Teng R, et al. Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing ad hoc PCI. *J Am Coll Cardiol*. 2016;67(6):603–13.
126. Jiang Z, Zhang R, Sun M, Liu Q, Wang S, Wang W, et al. Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. *Canadian Journal of Cardiology* [Internet]. 2018 Dec;34(12):1606–12. Available from: <https://onlinecjc.ca/action/showFullText?pii=S0828282X18310602>
127. Xu F, Feng W, Zhou Z, Zhang Y, Diao X, Hu S, et al. Antiplatelet effects of ticagrelor versus clopidogrel after coronary artery bypass graft surgery: A single-center randomized controlled trial. *Journal of Thoracic and Cardiovascular Surgery* [Internet]. 2019 Aug;158(2):430–437.e4. Available from: <https://www.jtcvs.org/action/showFullText?pii=S0022522318327867>
128. Li C, Liu M, Chen W, Jiang T, Ling L. Comparison of ticagrelor and clopidogrel on platelet function and prognosis in unstable angina. *Eur J Clin Pharmacol* [Internet]. 2022 Dec;78(12):1949. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9649465/>
129. Jain N, Corken A, Arthur JM, Ware J, Arulprakash N, Dai J, et al. Ticagrelor Inhibits Platelet Aggregation and Reduces Inflammatory Burden More than Clopidogrel in Patients with Stages 4 or 5 Chronic Kidney Disease. *Vascul Pharmacol* [Internet]. 2023 Feb;148:107143. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9998358/>
130. Yang Y, Chen W, Pan Y, Yan H, Meng X, Liu L, et al. Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Reactivity in Patients With Minor Stroke or TIA. *Front Neurol* [Internet]. 2020 Jun;11:527987. Available from: www.frontiersin.org
131. Sui Z, Qu P. Effect of ticagrelor and clopidogrel on platelet aggregation function after percutaneous coronary intervention in patients with acute coronary syndrome. *J Biol Regul Homeost Agents* [Internet]. 2019 May;33(2):439–45. Available from: <https://aber.apacsci.com/index.php/JBRHA/article/view/5391>
132. Kesieme EB, Iruolagbe CO, Omoregbee BI, Inuwa IM. Basic Overview of Conventional Coronary Angiography for Planning Cardiac Surgery. *Cureus* [Internet]. 2024 Jan 25 [cited 2025 Sep 5];16(1):e52942. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10894027/>
133. Sarkar A, Grigg WS, Lee JJ. TIMI Grade Flow. *StatPearls* [Internet]. 2023 Apr 24 [cited 2025 Sep 5]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482412/>
134. Pranata R, Yonas E, Chintya V, Alkatiri AA. Fragmented QRS and QRS Duration As a Marker of Myocardial Reperfusion Measured by Myocardial Blush Grade in Reperfusion Therapy: Systematic Review and Meta-Analysis. *Int J Angiol* [Internet]. 2019 [cited 2025 Sep 6];28(4):255–61. Available from: <https://pubmed.ncbi.nlm.nih.gov/31787825/>
135. Cruz PV, Palmes P, Bacalangco N. Prognostic Value of Myocardial Blush Grade in ST-elevation MI: A Systematic Review and Meta-analysis. *Interv Cardiol* [Internet]. 2022 [cited 2025 Sep 6];17. Available from: <https://pubmed.ncbi.nlm.nih.gov/35923767/>
136. Baralis G, Rossini R, Musumeci G. Antiplatelet therapy in STEMI undergoing primary PCI: when, which one and how long. *Minerva Cardioangiol* [Internet]. 2018 Aug 1 [cited 2025 Sep 6];66(4):422–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/29458246/>

137. Martinez Bravo G, Annarapu G, Carmona E, Nawarskas J, Clark R, Novelli E, et al. Platelets in Thrombosis and Atherosclerosis: A Double-Edged Sword. *American Journal of Pathology* [Internet]. 2024 Sep 1 [cited 2025 Sep 6];194(9):1608–21. Available from: <https://ajp.amjpathol.org/action/showFullText?pii=S0002944024002098>
138. Presume J, Gomes DA, Ferreira J, Albuquerque F, Almeida M, Uva MS, et al. Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis. *J Cardiovasc Pharmacol* [Internet]. 2023 Oct 28 [cited 2025 Sep 6];82(4):298–307. Available from: <https://pubmed.ncbi.nlm.nih.gov/37506674/>
139. Storey RF. Antiplatelet Therapy after PCI: The Art and Science of De-Escalation. *Circulation* [Internet]. 2024 Feb 20 [cited 2025 Sep 5];149(8):601–4. Available from: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067767>
140. Elahifar A, Rafati A, Alemzadeh-Ansari MJ, Pasebani Y, Naghshtabrizi B, Mohammadi Y, et al. The Comparison of the Initial TIMI Flow Grade in Acute ST-Elevation Myocardial Infarction Patients Receiving Ticagrelor vs. Clopidogrel before Undergoing Primary Percutaneous Coronary Intervention: A Prospective Cohort Study. *Cardiol Res Pract* [Internet]. 2024 [cited 2025 Sep 5];2024. Available from: <https://pubmed.ncbi.nlm.nih.gov/38348469/>
141. Bailleul C, Aissaoui N, Cayla G, Dillinger JG, Jouve B, Schiele F, et al. Prognostic impact of prepercutaneous coronary intervention TIMI flow in patients with ST-segment and non-ST-segment elevation myocardial infarction: Results from the FAST-MI 2010 registry. *Arch Cardiovasc Dis*. 2018 Feb 1;111(2):101–8.
142. Klein LW. Ticagrelor Versus Clopidogrel for Acute Coronary Syndrome: Have Things Changed? *American Journal of Cardiology* [Internet]. 2024 Jan 1 [cited 2025 Sep 6];210:315–6. Available from: <https://www.ajconline.org/action/showFullText?pii=S0002914923012559>
143. Schaaf MJ, Mewton N, Rioufol G, Angoulvant D, Cayla G, Delarche N, et al. Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct size and microvascular obstruction in STEMI patients. *J Cardiol* [Internet]. 2016 Mar 1 [cited 2025 Sep 6];67(3):248–53. Available from: <https://pubmed.ncbi.nlm.nih.gov/26116981/>
144. Geravandi M, Nourabi M, Navabifar S, Geravandi M, Hooshanginezhad Z, Zand S, et al. A comparison of the effects of ticagrelor and clopidogrel in patients with acute ST-segment elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. *BMC Pharmacology and Toxicology* [Internet]. 2024 Dec 1 [cited 2025 Sep 6];25(1):1–13. Available from: <https://bmcpharmacoltoxcol.biomedcentral.com/articles/10.1186/s40360-024-00817-8>
145. Fakhry EE, Etriby AM El, Nayel AE, Fakhry EE, Etriby AM El, Nayel AE. Comparison between preoperative loading dose of ticagrelor versus clopidogrel on myocardial perfusion in type ii diabetic patients presenting with anterior wall myocardial infarction. *International Journal of the Cardiovascular Academy* [Internet]. 2021 Apr 1 [cited 2025 Sep 5];7(2):55–9. Available from: <https://orcid.org/0000-0001-5604-3104>
146. Li Y, Ye Z, Guo Z, Xie E, Wang M, Zhao X, et al. Ticagrelor vs. clopidogrel for coronary microvascular dysfunction in patients with STEMI: a meta-analysis of randomized controlled trials. *Front Cardiovasc Med* [Internet]. 2023 [cited 2025 Sep 5];10:1102717. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10233131/>
147. Beavers CJ, Patel P, Naqvi IA. Clopidogrel. *Antiplatelet Therapy in Cardiovascular Disease* [Internet]. 2025 Jan 19 [cited 2025 Sep 6];160–5. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470539/>
148. Ozyuncu N. Antiplatelet Therapy in Heart Disease. *Rev Cardiovasc Med* [Internet]. 2025 Jun 1 [cited 2025 Sep 6];26(6):36522. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC12230833/>

149. Qiu X, Li X, Fu K, Chen W, Chen W. The effect of ticagrelor on coronary microvascular function after PCI in patients with ACS compared to clopidogrel: A systematic review and meta-analysis. *PLoS One* [Internet]. 2023 Aug 1 [cited 2025 Sep 5];18(8). Available from: <https://pubmed.ncbi.nlm.nih.gov/37643179/>
150. Reiss AB, Grossfeld D, Kasselmann LJ, Renna HA, Vernice NA, Drewes W, et al. Adenosine and the Cardiovascular System. *Am J Cardiovasc Drugs* [Internet]. 2019 Oct 1 [cited 2025 Sep 6];19(5):449–64. Available from: <https://pubmed.ncbi.nlm.nih.gov/30972618/>
151. Guo Z, Yang Z, Song Z, Li Z, Xiao Y, Zhang Y, et al. Inflammation and coronary microvascular disease: relationship, mechanism and treatment. *Front Cardiovasc Med* [Internet]. 2024 [cited 2025 Sep 6];11:1280734. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11148780/>
152. Tucker B, Vaidya K, Cochran BJ, Patel S. Inflammation during Percutaneous Coronary Intervention—Prognostic Value, Mechanisms and Therapeutic Targets. *Cells* [Internet]. 2021 Jun 1 [cited 2025 Sep 6];10(6):1391. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC8230292/>
153. Pasquini S, Contri C, Borea PA, Vincenzi F, Varani K. Adenosine and Inflammation: Here, There and Everywhere. *Int J Mol Sci* [Internet]. 2021 Jul 2 [cited 2025 Sep 6];22(14):7685. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC8304851/>
154. Correia AS, Vale N. Exploring Oxidative Stress in Disease and Its Connection with Adenosine. *Oxygen 2024*, Vol 4, Pages 325-337 [Internet]. 2024 Aug 19 [cited 2025 Sep 6];4(3):325–37. Available from: <https://www.mdpi.com/2673-9801/4/3/19/htm>
155. Vilahur G, Gutiérrez M, Casani L, Varela L, Capdevila A, Pons-Lladó G, et al. Protective Effects of Ticagrelor on Myocardial Injury After Infarction. *Circulation* [Internet]. 2016 Nov 29 [cited 2025 Sep 6];134(22):1708–19. Available from: <https://pubmed.ncbi.nlm.nih.gov/27789556/>
156. Sokratous S, Mitsis A, Khatlab E, Karelakis D, Velidakis N, Kadoglou NPE. Coronary Microvascular Disease Early After Myocardial Infarction: Diagnostic Approach and Prognostic Value—A Narrative Review. *Biomedicines* [Internet]. 2025 Jun 1 [cited 2025 Sep 6];13(6):1289. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC12189317/>
157. Marxer CA, Hjemdahl P, Carrero JJ, Fu EL. Comparative effectiveness and safety of dual antiplatelet therapy with ticagrelor vs. clopidogrel in older adults with acute coronary syndrome: a target trial emulation study. *Eur Heart J Cardiovasc Pharmacother*. 2025 May 14;
158. Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT, et al. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. *JAMA Intern Med*. 2020 Mar 1;180(3):420.
159. Gao S, Xu H, Huang S, Yuan J, Yu M. Real-World Use of Clopidogrel and Ticagrelor in Patients With Myocardial Infarction With Nonobstructive Coronary Arteries: Patient Characteristics and Long-Term Outcomes. *Front Cardiovasc Med*. 2021 Dec 21;8.
160. You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, et al. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. *JAMA*. 2020 Oct 27;324(16):1640.
161. Qiu M, Zhi X, Liu H, Liang Z, Wang B, Xu K, et al. Impact of Ticagrelor vs. Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Left Main Percutaneous Coronary Intervention. *Cardiology Discovery*. 2025 Mar 15;5(1):39–46.

162. Varenhorst C, Alström U, Braun OÖ, Storey RF, Mahaffey KW, Bertilsson M, et al. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. *Heart*. 2014 Nov 15;100(22):1762–9.
163. Almendro-Delia M, Hernández-Meneses B, Padilla-Rodríguez G, Blanco-Ponce E, Arboleda-Sánchez JA, Rodríguez-Yáñez JC, et al. Timing of P2Y12 Inhibitor Administration in Patients With STEMI Undergoing Primary PCI. *J Am Coll Cardiol*. 2024 Jun;83(25):2629–39.
164. Hakeem A, Shah JA, Kumar R, Ali A, Lakho AA, Zeeshan H, et al. Twice-A-Day CLOpidogrel vs Ticagrelor to Reduce Short-Term MACE after Primary PCI: The TADCLOT Trial. *JACC [Internet]*. 2025 Aug 30 [cited 2025 Sep 13]; Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0735109725075497>
165. Zhai Y, Shang H, Li Y, Zhang N, Zhang J, Wu S. A Systematic Review of risk factors for major adverse cardiovascular events in patients with coronary heart disease who underwent percutaneous coronary intervention. *Front Physiol [Internet]*. 2025 [cited 2025 Sep 13];16:1514585. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC12014560/>
166. Chen W, Tan X, Du X, Li Q, Yuan M, Ni H, et al. Prediction models for major adverse cardiovascular events following ST-segment elevation myocardial infarction and subgroup-specific performance. *Front Cardiovasc Med [Internet]*. 2023 [cited 2025 Sep 13];10:1181424. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10167292/>
167. Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, et al. Clopidogrel pharmacogenetics state-of-the-art review and the TAILOR-PCI study. *Circ Cardiovasc Interv [Internet]*. 2019 Apr 1 [cited 2025 Sep 13];12(4):7811. Available from: <https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.119.007811>
168. Giantini A, Timan IS, Dharma R, Sukmawan R, Setiabudy R, Alwi I, et al. The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention. *Front Cardiovasc Med [Internet]*. 2023 Feb 8 [cited 2025 Sep 13];9:1027892. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9944402/>
169. Biswas M, Sukasem C, Khatun Kali MS, Ibrahim B. Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. *Pharmacogenomics [Internet]*. 2022 Feb 1 [cited 2025 Sep 13];23(3):207–20. Available from: <https://pubmed.ncbi.nlm.nih.gov/35042400/>
170. Gager GM, Biesinger B, Hofer F, Winter MP, Hengstenberg C, Jilma B, et al. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. *Vascul Pharmacol*. 2020 Dec 1;135:106806.
171. Hamzic-Mehmedbasic A. Inflammatory Cytokines as Risk Factors for Mortality After Acute Cardiac Events. *Med Arch [Internet]*. 2016 Jul 27 [cited 2025 Sep 13];70(4):252–5. Available from: <https://pubmed.ncbi.nlm.nih.gov/27703283/>
172. Tøllefsen IM, Shetelig C, Seljeflot I, Eritsland J, Hoffmann P, Andersen GØ. High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI. *Open Heart [Internet]*. 2021 Dec 1 [cited 2025 Sep 13];8(2):e001869. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC8693166/>
173. Neef PA, Loy O, Brennan AL, Ajani AE, Reid C, Dinh D, et al. Long-term outcomes of patients with late presentation STEMI undergoing percutaneous coronary revascularization. *Eur Heart J [Internet]*. 2023 Nov 9 [cited 2025 Sep 13];44(Supplement_2). Available from: <https://dx.doi.org/10.1093/eurheartj/ehad655.1331>
174. Shenoy N, Devasia T, Shenoy N, Devasia T. Comparison of Outcomes between Early and Late Presentation of ST-elevation Myocardial Infarction in Patients with Cardiogenic Shock. *International Journal of the Cardiovascular Academy*. 2024 Sep 1;10(3):53–9.

175. Kochan A, Lee T, Moghaddam N, Milley G, Singer J, Cairns JA, et al. Reperfusion Delays and Outcomes among Patients with ST-Segment-Elevation Myocardial Infarction with and Without Cardiogenic Shock. *Circ Cardiovasc Interv* [Internet]. 2023 Jun 1 [cited 2025 Sep 13];16(6):349–57. Available from: <https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.122.012810>
176. Ki YJ, Kang J, Yang HM, Woo Park K, Kang HJ, Koo BK, et al. Immediate Compared With Delayed Percutaneous Coronary Intervention for Patients With ST-Segment-Elevation Myocardial Infarction Presenting ≥ 12 Hours After Symptom Onset Is Not Associated With Improved Clinical Outcome. *Circ Cardiovasc Interv* [Internet]. 2021 May 1 [cited 2025 Sep 13];14(5):E009863. Available from: <https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.120.009863>
177. Zhou S, Qiu M, Wang K, Li J, Li Y, Han Y. Triglyceride to high density lipoprotein cholesterol ratio and major adverse cardiovascular events in ACS patients undergoing PCI. *Scientific Reports* 2024 14:1 [Internet]. 2024 Dec 30 [cited 2025 Sep 13];14(1):1–10. Available from: <https://www.nature.com/articles/s41598-024-82064-9>
178. Sun CX, Hu LQ, Li XY, Zhang XN, Chen JY, Li DX, et al. Triglyceride-glucose index's link to cardiovascular outcomes post-percutaneous coronary intervention in China: a meta-analysis. *ESC Heart Fail* [Internet]. 2024 Jun 1 [cited 2025 Sep 13];11(3):1317. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11098636/>
179. Guliyev I, Algül E, Gökalp G, Aydınılmaz F, Özbeyaz NB, Sunman H. Effect of Ticagrelor on Left Ventricular Function in Patients with Mildly Reduced Ejection Fraction after Acute Myocardial Infarction. *International Journal of Cardiovascular Sciences*. 2024 Mar 6;37.
180. Teoli D, Bhardwaj A. Quality Of Life. 2023 Mar 27 [cited 2025 Sep 7]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK536962/>
181. Komalasari R, Nurjanah, Yoche MM. Quality of Life of People with Cardiovascular Disease: A Descriptive Study. *Asian Pac Isl Nurs J* [Internet]. 2019 [cited 2025 Sep 7];4(2):92. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6571918/>
182. Sisay T, Mulate M, Hailu T, Belete TM. The prevalence of depression and anxiety among cardiovascular patients at University of Gondar specialized hospital using beck's depression inventory II and beck anxiety inventory: A cross-sectional study. *Heliyon*. 2024 Jan 30;10(2):e24079.
183. Lee C, Lee SC, Shin YS, Park S, Won KB, Ann SH, et al. Severity, Progress, and Related Factors of Mood Disorders in Patients with Coronary Artery Disease: A Retrospective Study. *Healthcare (Basel)* [Internet]. 2020 [cited 2025 Sep 7];8(4). Available from: <https://pubmed.ncbi.nlm.nih.gov/33339355/>
184. Knowles KA, Olatunji BO. Specificity of Trait Anxiety in Anxiety and Depression: Meta-Analysis of the State-Trait Anxiety Inventory. *Clin Psychol Rev* [Internet]. 2020 Dec 1 [cited 2025 Sep 7];82:101928. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC7680410/>
185. Kadayıf A, Cengiz Açıl H. Perceived stress and anxiety levels of patients undergoing coronary angiography. *Journal of International Medical Research* [Internet]. 2025 May 1 [cited 2025 Sep 7];53(5). Available from: <https://journals.sagepub.com/doi/full/10.1177/03000605251340168>
186. Soloveva A, Gale CP, Han NT, Hurdus B, Aktaa S, Palin V, et al. Associations of health-related quality of life with major adverse cardiovascular and cerebrovascular events for individuals with ischaemic heart disease: systematic review, meta-analysis and evidence mapping. *Open Heart* [Internet]. 2023 Oct 27 [cited 2025 Sep 7];10(2). Available from: <https://openheart.bmj.com/content/10/2/e002452>

187. Moon H, Jo YS, Kim SJ, Jo S, Park K. Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome. *Health Qual Life Outcomes* [Internet]. 2021 Dec 1 [cited 2025 Sep 7];19(1):242. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC8520288/>
188. Munyombwe T, hall M, Bernadette Dondo T, alabas O, gerard O, West robert M, et al. Quality of life trajectories in survivors of acute myocardial infarction: a national longitudinal study *Coronary artery disease*. *Heart* [Internet]. 2020 [cited 2025 Sep 7];106:33–9. Available from: <http://heart.bmj.com/>
189. Conradie A, Atherton J, Chowdhury E, Duong MN, Schwarz N, Worthley S, et al. Health-Related Quality of Life (HRQoL) and the Effect on Outcome in Patients Presenting with Coronary Artery Disease and Treated with Percutaneous Coronary Intervention (PCI): Differences Noted by Sex and Age. *J Clin Med* [Internet]. 2022 Sep 1 [cited 2025 Sep 7];11(17):5231. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9457487/>
190. Legaki F, Babatsikou F, Koutis C, Polikandrioti M. State and trait anxiety in islander cardiac patients: associated factors and the impact of perceived social support. *Arch Med Sci Atheroscler Dis* [Internet]. 2020 May 29 [cited 2025 Sep 7];5(1):e85. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC7277444/>
191. Kim Y. Health-Related Quality of Life in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Cross-Sectional Study. *J Nurs Res* [Internet]. 2021 [cited 2025 Sep 7];30(1):E186. Available from: <https://pubmed.ncbi.nlm.nih.gov/34720107/>
192. Batóg P, Rencz F, Péntek M, Gulácsi L, Filipiak KJ, Rupel VP, et al. EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. *Kardiol Pol* [Internet]. 2018 May 11 [cited 2025 Sep 7];76(5):860–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/29350378/>